Marengo Therapeutics Presents Phase 2 STARt-001 Results at ESMO 2026 Demonstrating Tissue-Agnostic Single-Agent Activity of Invikafusp Alfa in TMB-H Solid Tumors Mostly Unresponsive to Immune Checkpoint Blockade
Objective responses observed across eight distinct tumor types, including breast, colorectal, endometrial, gastroesophageal junction, gastric, head and neck, non-small cell lung and bladder cancers Tumor shrinkage observed in 56% of evaluable patients, with an 18% objective response rate...
Extrait seulement — cet éditeur protège son texte. Lisez le communiqué complet à la source.
Forfait Gratuit · Plus 29 $ CA ou Pro 99 $ CA/mois


